Neutrophils dominate the immune cell composition in non-small cell lung cancer

The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials combining novel immunotherapeutics with immune checkpoint blockade have been initiated. Unfortunately, these trials have been desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kargl, Julia, Busch, Stephanie E., Yang, Grace H. Y., Kim, Kyoung-Hee, Hanke, Mark L., Metz, Heather E., Hubbard, Jesse J., Lee, Sylvia M., Madtes, David K., McIntosh, Martin W., Houghton, A. McGarry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296654/
https://www.ncbi.nlm.nih.gov/pubmed/28146145
http://dx.doi.org/10.1038/ncomms14381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296654/
https://www.ncbi.nlm.nih.gov/pubmed/28146145
http://dx.doi.org/10.1038/ncomms14381

Ejemplares similares